Diabetes drug empagliflozin studied for kidney disease mineral effects

NCT ID NCT06435858

Recruiting now Knowledge-focused Sponsor: Cantonal Hospital Graubuenden Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial is testing whether the diabetes drug empagliflozin changes how the kidneys handle calcium, phosphate, and magnesium in people with autosomal dominant polycystic kidney disease (ADPKD). Forty adults will take either empagliflozin or a placebo for two weeks, then switch after a two-week break. The goal is to better understand electrolyte balance, not to treat the disease itself.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin
What this could lead to: If successful, this could help doctors understand how SGLT2 inhibitors affect electrolyte balance in ADPKD, potentially guiding future treatment strategies.
What could go wrong: This is a small, early-phase study (40 people) looking only at short-term effects over 2 weeks. It is not designed to test long-term benefits or risks, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant polycystic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

Contacts and locations

Locations

Cantonal Hospital Graubuenden
RECRUITING

Chur, Kanton Graubünden, 7000, Switzerland
University Hospital Zurich, Division of Nephrology
RECRUITING

Zurich, Canton of Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.